NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee D meeting minutes

**Minutes:** Confirmed

**Date:** Thursday 4 April 2024

**Location:** Via Zoom

## Attendees

Committee members present

1. Dr Megan John (Chair) Present for all items
2. Dr Raju Reddy (Vice-chair) Present for all items
3. Martin Bradley Present for all items
4. Dr Matthew Bradley Present for all items
5. Paul Caulfield Present for all items
6. Professor Sofia Dias Present for all items
7. Dr Andrew Hitchings Present for all items
8. Dr Guy Makin Present for all items
9. Giles Monnickendam Present for all items
10. Dr Nathan Moore Present for all items
11. Dr Paula Parvulescu Present for all items
12. Carole Pitkeathley Items 1.1 to 4.1.3, Items 5.1.3

to 5.2.2

1. Dr Ben Searle Present for all items
2. Sophia Steer Present for all items
3. Will Sullivan Present for all items
4. Dr Zenas Yiu Present for all items

NICE staff (key players) present

Jacoline Bouvy, Programme Director Items 1.1 to 4.2.2

Linda Landells, Associate Director Items 1.1 to 4.2.2

Kate Moore, Project Manager Items 1.1 to 4.2.2

Nigel Gumbleton, Heath Technology Assessment Adviser Items 1.1 to 4.2.2

Emily Leckenby, Heath Technology Assessment Analyst Items 1.1 to 4.2.2

Ian Watson, Associate Director Items 5.1.1 to 5.2.2

Leena Issa, Project Manager Items 5.1.1 to 5.2.2

Lizzie Walker, Heath Technology Assessment Adviser Items 5.1.1 to 5.2.2

Emma Douch, Heath Technology Assessment Analyst Items 5.1.1 to 5.2.2

External assessment group representatives present

Dr Janette Greenhalgh, Liverpool Reviews and Implementation Group (LRIG)

Items 1.1 to 4.1.3

James Mahon, Liverpool Reviews and Implementation Group (LRIG)

Items 1.1 to 4.1.3

Dr Maiwenn Al, Kleijnen Systematic Reviews Items 5.1.1 to 5.1.3

Dr Nigel Armstrong, Kleijnen Systematic Reviews Items 5.1.1 to 5.1.3

Clinical, Patient & NHS England experts present

Layla Lawson, Patient expert, nominated by the Essenelle Foundation

Items 1.1 to 4.1.3

Dr Sanjeev Patel, IMF lead, nominated by NHS England Items 1.1 to 4.2.2

Dr Charles Hay, Professor of Haemostasis and Thrombosis, Consultant Haematologist Director of the UK National Haemophilia Database (NHD), Clinical expert, nominated by Swedish Orphan Biovitrum Items 5.1.1 to 5.1.3

Dr Alice Taylor, Haematology Consultant, Clinical expert, nominated by UK Haemophilia Centre Doctors' Organisation (UKHCDO) Items 5.1.1 to 5.1.3

Edward Rippingale-Combes, NHS Clinical Research Nurse, Patient expert, nominated by The Haemophilia Society

Items 5.1.1 to 5.1.3

Clive Smith, Chair of the Haemophilia Society Board, Patient expert, nominated by The Haemophilia Society

Items 5.1.1 to 5.1.3

*Please note that alongside the attendees listed in this document, there were additional NICE Staff present in this meeting. These attendees were not involved in the decision making or discussions.*

## Minutes

### Introduction to the meeting

* 1. The Chair, Dr Megan John, welcomed members of the committee and other attendees present to the meeting.
  2. The Chair noted apologies from Andrew Fox, Dr Robert Hodgson, Dr Bernard Khoo, Dr Ivan Koychev, Dr Philip Mallender, and Professor David Meads.

### News and announcements

* 1. The Chair acknowledged it was the last meeting for Dr Andrew Hitchings and thanked him for his service to the committee.

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Wednesday 6 March 2024

### Appraisal of Voxelotor for treating haemolytic anaemia caused by sickle cell disease [ID1403]

* 1. Part 1 – Open session
     1. The Chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Pfizer.
     2. The Chair asked all committee members and experts, external assessment group representatives, and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta10505).
     3. The Chair led a discussion of the consultation comments presented to the committee. This information was presented to the committee by the Chair.
  2. Part 2 – Closed session (company representatives, external assessment group representatives, and members of the public were asked to leave the meeting)
     1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10505>

### Appraisal of Efanesoctocog alfa for treating and preventing bleeding episodes in haemophilia A [ID6170]

* 1. Part 1 – Open session
     1. The Chair welcomed the invited experts, external assessment group representatives, and company representatives from Swedish Orphan Biovitrum. Efanesoctocog alfa had not received regulatory approval, so this committee discussion was held without members of the public.
     2. The Chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta11106).
     3. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Dr Guy Makin, Paul Caulfield, and Will Sullivan.
  2. Part 2 – Closed session (company representatives, clinical and patient experts, and external assessment group representatives were asked to leave the meeting)
     1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta11106>

### Date of the next meeting

The next meeting of the Technology Appraisal Committee D will be held on Thursday 9 May 2024 and will start promptly at 09:00am.